Selective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical Remarks
Open accessThe DOI matches its Crossref record.
Abstract
Non steroidal anti-inflammatory drugs (NSAIDs) are still the most commonly used remedies for rheumatic diseases. But NSAIDs produce serious adverse effects, the most important being gastric injury up to gastric ulceration and renal damage. Several strategies have been adopted in order to avoid these shortcomings, especially gastrointestinal toxicity. So, non steroidal anti-inflammatory drugs have been associated with gastroprotective agents that counteract the damaging effects of prostaglandin synthesis suppression: however, a combination therapy introduces problems of pharmacokinetics, toxicity, and patient s compliance. Also incorporation of a nitric oxide (NO)-generating moiety into the molecule of several NSAIDs was shown to greatly attenuate their ulcerogenic activity: however, several findings suggest a possible involvement of NO in the pathogenesis of arthritis and subsequent tissue destruction. A most promising approach seemed to be the preparation of novel NSAIDs, specific for the inducible isoform of cyclooxygenase (COX-2): they appear to be devoid of gastrointestinal toxicity, in that they spare mucosal prostaglandin synthesis. However, a number of recent studies raised serious questions about the two central tenets that support this approach, namely that the prostaglandins that mediate inflammation and pain are produced solely via COX-2 and that the prostaglandins that are important in gastrointestinal and renal function are produced solely via COX-1. So, increasing evidence shows that COX-2 (not only COX-1) also plays a physiological role in several body functions and that, conversely, COX-1 (not only COX-2) may also be induced at sites of inflammation. Moreover, COX-2 selective NSAIDs have lost the cardiovascular protective effects of non-selective NSAIDs, effects which are mediated through COX-1 inhibition (in addition, COX-2 has a role in sustaining vascular prostacyclin production). The products generated by the 5-lipoxygenase pathway (leukotrienes) are particularly important in inflammation: indeed, leukotrienes increase microvascular permeability and are potent chemotactic agents; moreover, inhibition of 5-lipoxygenase indirectly reduces the expression of TNF-alpha (a cytokine that plays a key role in inflammation). This explains the efforts to obtain drugs able to inhibit both 5-lipoxygenase and cyclooxygenases: the so-called dual acting anti-inflammatory drugs. Such compounds retain the activity of classical NSAIDs, while avoiding their main drawbacks, in that curtailed production of gastroprotective prostaglandins is associated with a concurrent curtailed production of the gastro-damaging and bronchoconstrictive leukotrienes. Moreover, thanks to their mechanism of action, dual acting anti-inflammatory drugs could not merely alleviate symptoms of rheumatic diseases, but might also satisfy, at least in part, the criteria of curative drugs. Indeed, leukotrienes are pro-inflammatory, increase microvascular permeability, are potent chemotactic agents and attract eosinophils, neutrophils and monocytes into the synovium. Finally, recent data strongly suggest that dual inhibitors may have specific protective activity also in neurodegeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Still being checked.
Cited by
Paracetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
Self-citationInflammation and depression: a causal or coincidental link to the pathophysiology?
Leonard, B. E. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.69 · Cited by 409
Choi, S.-H., Aid, S., & Bosetti, F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.01.002 · Cited by 402
Potential Analgesic Mechanisms of Acetaminophen
Smith, H. (2009) · Pain Physician · doi:10.36076/ppj.2009/12/269 · Cited by 245
Sohail, R., Mathew, M., Patel, K. K., Reddy, S. A., Haider, Z., Naria, M., Habib, A., Abdin, Z. U., Razzaq Chaudhry, W., & Akbar, A. (2023) · Cureus · doi:10.7759/cureus.37080 · Cited by 239
Rostom, S. A. F., El-Ashmawy, I. M., Abd El Razik, H. A., Badr, M. H., & Ashour, H. M. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.11.035 · Cited by 219
Harrak, Y., Casula, G., Basset, J., Rosell, G., Plescia, S., Raffa, D., Cusimano, M. G., Pouplana, R., & Pujol, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100398z · Cited by 199
Chen, J., & Lariviere, W. R. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.006 · Cited by 196
Recent advancements in the development of heterocyclic anti-inflammatory agents
Sharma, S., Kumar, D., Singh, G., Monga, V., & Kumar, B. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112438 · Cited by 161
Kroon, F. P. B., van der Burg, L. R. A., Ramiro, S., Landewé, R., Buchbinder, R., Falzon, L., & van der Heijde, D. M. F. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010952.pub2 · Cited by 159
Chiu, F.-L., & Lin, J.-K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.05.049 · Cited by 137
P2X7 receptor‐stimulation causes fever via PGE2 and IL‐1β release
Barberà‐Cremades, M., Baroja‐Mazo, A., Gomez, A. I., Machado, F., Di Virgilio, F., & Pelegrín, P. (2012) · The FASEB Journal · doi:10.1096/fj.12-205765 · Cited by 142
Sharma, V., Bhatia, P., Alam, O., Naim, M. J., Nawaz, F., Sheikh, A. A., & Jha, M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103007 · Cited by 142
Mukhopadhyay, N., Shukla, A., Makhal, P. N., & Kaki, V. R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14569 · Cited by 142
Leonard, B. E. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.018 · Cited by 129
Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis
Seo, M., & Oh, D. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.04.003 · Cited by 121
Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives
Becerra, D., Abonía, R., & Castillo, J. (2022) · Molecules · doi:10.3390/molecules27154723 · Cited by 116
Park, H. J., Lee, H., Choi, M. S., Son, D. J., Song, H. S., Song, M. J., Lee, J. M., Han, S., Kim, Y., & Hong, J. T. (2008) · Journal of Inflammation · doi:10.1186/1476-9255-5-7 · Cited by 114
Park, H. J., Son, D. J., Lee, C. W., Choi, M. S., Lee, U. S., Song, H. S., Lee, J. M., & Hong, J. T. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.023 · Cited by 107
Xian, Y., Mao, Q., Ip, S., Lin, Z., & Che, C. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.08.014 · Cited by 107
Xian, Y., Li, Y., Ip, S., Lin, Z., Lai, X., & Su, Z. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.233 · Cited by 106
Chu, H., Tang, Q., Huang, H., Hao, W., & Wei, X. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.11.018 · Cited by 106
Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking
Hoggatt, J., & Pelus, L. M. (2010) · Leukemia · doi:10.1038/leu.2010.216 · Cited by 102
Abdelgawad, M. A., Bakr, R. B., & Azouz, A. A. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.028 · Cited by 97
The role of serratiopeptidase in the resolution of inflammation
Tiwari, M. (2017) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.01.003 · Cited by 96
Kaduševičius, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126637 · Cited by 58
Jung, H.-W., Seo, U.-K., Kim, J., Leem, K., & Park, Y. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.12.024 · Cited by 89
Choi, H.-G., Lee, D., Li, B., Choi, Y. H., Lee, S., & Kim, Y. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.04.016 · Cited by 86
Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80
“Therefore, COX2 inhibition was considered to be a therapeutic strategy for inflammatory diseases, including AD (53).”
BackgroundMajor role of adipocyte prostaglandin E2 in lipolysis-induced macrophage recruitment
Hu, X., Cifarelli, V., Sun, S., Kuda, O., Abumrad, N. A., & Su, X. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066530 · Cited by 77
Kim, M. J., Kim, D. W., Park, J. H., Kim, S. J., Lee, C. H., Yong, J., Ryu, E. J., Cho, S. B., Yeo, H. J., Hyeon, J., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.005 · Cited by 70
Celotti, F., & Durand, T. (2003) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s1098-8823(03)00039-x · Cited by 69
Effects of zileuton and montelukast in mouse experimental spinal cord injury
Genovese, T., Rossi, A., Mazzon, E., Paola, R. D., Muià, C., Caminiti, R., Bramanti, P., Sautebin, L., & Cuzzocrea, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707577 · Cited by 64
Syam, S., Bustamam, A., Abdullah, R., Sukari, M. A., Hashim, N. M., Mohan, S., Looi, C. Y., Wong, W. F., Yahayu, M. A., & Abdelwahab, S. İ. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.02.051 · Cited by 64
Li, S., Tsai, S., Chiang, C., Chung, C., Chuang, T.-J., Tseng, C., Jiang, W., Huang, G., Lin, C., Yang, Y., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104333 · Cited by 64
Moschona, A., & Liakopoulou-Kyriakides, M. T. (2018) · Journal of Microencapsulation · doi:10.1080/02652048.2018.1462415 · Cited by 63
Sayed, M. T. E., El‐Sharief, M. A. M. S., Zarie, E. S., Morsy, N. M., El‐Sheakh, A. R., Voronkov, A. V., Berishvili, V. P., & Hassan, G. S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.043 · Cited by 59
Gaddi, A. V., Cicero, A. F. G., & Pedro, E. (2004) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2003.10.001 · Cited by 59
Reddy, K. K., Rajan, V. K. V., Gupta, A., Aparoy, P., & Reddanna, P. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1101-4 · Cited by 58
Sex differences in innate immunity and its impact on opioid pharmacology
Doyle, H. H., & Murphy, A. Z. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23852 · Cited by 55
Cooper, D. L., & Harirforoosh, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113558 · Cited by 56
Jung, H. W., Ramalingam, M., Park, J. H., Boo, Y. C., Park, K. M., & Park, Y. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.10.010 · Cited by 56
Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as anti-inflammatory agents
Tageldin, G. N., Fahmy, S. M., Ashour, H. M. A., Khalil, M. A., Nassra, R. A., & Labouta, I. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.03.030 · Cited by 54
Anti-inflammatory activity of (−)-aptosimon isolated from Daphne genkwa in RAW264.7 cells
Lee, M.-Y., Park, B., Kwon, O., Yuk, J.-E., Oh, S., Kim, H., Lee, H., & Ahn, K. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.012 · Cited by 52
Gomes, A. S., Fernandes, E. G. R., Silva, A. M. S., Pinto, D. C. G. A., Santos, C. M. M., Cavaleiro, J. A. S., & Lima, J. L. F. C. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.03.028 · Cited by 51
Dual inhibition: a novel promising pharmacological approach for different disease conditions
Patyar, S., Prakash, A., & Medhi, B. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01236.x · Cited by 39
Arya, S., Nikhil, K., Roy, P., & Sondhi, S. M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.10.046 · Cited by 49
Ahn, E. H., Kim, D. W., Kang, H. W., Shin, M. J., Won, M. H., Kim, J., Kim, D. J., Kwon, O., Kang, T., Han, K. H., et al. (2010) · Toxicology · doi:10.1016/j.tox.2010.08.004 · Cited by 48
Glycyrrhizin ameliorates metabolic syndrome-induced liver damage in experimental rat model
Sil, R., Ray, D., & Chakraborti, A. S. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2523-y · Cited by 46
Puangpraphant, S., Berhow, M. A., & de Mejía, E. G. (2010) · Food Chemistry · doi:10.1016/j.foodchem.2010.10.023 · Cited by 46
Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Chand, S., Mehta, N., Bahia, M. S., Dixit, A., & Silakari, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651625 · Cited by 46
Jones, P., & Lamdin, R. (2010) · Clinical Drug Investigation · doi:10.2165/11533350-000000000-00000 · Cited by 45
Tajdari, M., Peyrovinasab, A., Bayanati, M., Rabbani, M. I. M., Abdolghaffari, A. H., & Zarghi, A. (2024) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-151312 · Cited by 42
Shoeb, M., Kodali, V., Farris, B. Y., Bishop, L. M., Meighan, T. G., Salmen, R., Eye, T., Roberts, J. R., Zeidler-Erdely, P. C., Erdely, A., et al. (2017) · Nanotoxicology · doi:10.1080/17435390.2017.1349200 · Cited by 42
Alterations of tendons in diabetes mellitus: what are the current findings?
Shi, L., Rui, Y., Li, G., & Wang, C. (2015) · International Orthopaedics · doi:10.1007/s00264-015-2775-x · Cited by 40
Blasco, J., & Trombini, C. (2023) · Water Emerging Contaminants & Nanoplastics · doi:10.20517/wecn.2023.06 · Cited by 39
Roberts, E. S., LARE, K. A. V., Marable, B. R., & Salminen, W. F. (2008) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2008.01043.x · Cited by 38
Non-steroidal anti-inflammatory drugs in athletes
Lippi, G., Franchini, M., Guidi, G. C., & Kean, W. F. (2006) · British Journal of Sports Medicine · doi:10.1136/bjsm.2006.027342 · Cited by 38
Kim, D. W., Lee, S. H., Shin, M. J., Kim, K., Ku, S., Youn, J. K., Cho, S. B., Park, J. H., Lee, C. H., Son, O., et al. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.11.041 · Cited by 37
Li, P., Ye, J., Zeng, S., & Yang, C. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.08.073 · Cited by 37
Asadi, P., Alvani, M., Hajhashemi, V., Rostami, M. R., & Khodarahmi, G. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130760 · Cited by 37
Pingili, R. B., Pawar, A. K., & Challa, S. R. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1008012 · Cited by 37
Trihydroxyflavones with antioxidant and anti‐inflammatory efficacy
Gomes, A. S., Couto, D., Alves, A., Dias, I., Freitas, M., Porto, G., Duarte, J. A., & Fernandes, E. G. R. (2012) · BioFactors · doi:10.1002/biof.1033 · Cited by 36
Mohamed, L. W., El‐Badry, O. M., El-Ansary, A. K., & Ismael, A. S. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.04.012 · Cited by 35
Lee, S. H., Kim, D. W., Eom, S. A., Jun, S., Park, M.-Y., Kim, D., Kwon, H., Kwon, H. Y., Han, K. H., Park, J., et al. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.6.036 · Cited by 34
Kroon, F. P. B., van der Burg, L. R. A., Ramiro, S., Landewé, R., Buchbinder, R., & van der Heijde, D. M. F. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010952 · Cited by 34
Roome, T., Dar, A., Naqvi, S., Ali, S., & Choudhary, M. I. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.08.025 · Cited by 33
Kim, M. J., Jeong, H. J., Kim, D. W., Sohn, E. J., Jo, H. S., Kim, D., Kim, H. A., Park, E. Y., Park, J. H., Son, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086034 · Cited by 31
Synthesis and biological properties of aryl methyl sulfones
Navarro, L., Rosell, G., Sánchez, S., Boixareu, N., Pors, K., Pouplana, R., Campanera, J. M., & Pujol, M. D. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.038 · Cited by 31
Saravanan, G., Alagarsamy, V., & Dineshkumar, P. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0262-8 · Cited by 30
Özkay, Ü. D., Özkay, Y., & Can, Ö. D. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9300-y · Cited by 30
Activity and potential role of licofelone in the management of osteoarthritis
Cicero, A. F. G., & Laghi, L. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.73 · Cited by 30
Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits
Elshazly, A. H. M., Elgohary, A. A., Elshazly, L. H. M., & El-Hossary, G. G. (2008) · Acta Pharmaceutica · doi:10.2478/v10007-008-0009-0 · Cited by 31
Yacoub, A. S., Ammar, H. O., Ibrahim, M. M., Mansour, S. M., & Hoffy, N. M. E. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2069882 · Cited by 29
An Ethnopharmacological Study of Medicinal Plants in New South Wales
Brouwer, N., Liu, Q. F., Harrington, D. T., Kohen, J., Vemulpad, S. R., Jamie, J. F., Randall, M., & Randall, D. (2005) · Molecules · doi:10.3390/10101252 · Cited by 29
Tacrolimus and Nonsteroidal Anti-Inflammatory Drugs: An Association to Be Avoided
Soubhia, R. M. C., Mendes, G. E. F., Mendonça, F. Z., Baptista, M. A. S. F., Cipullo, J. P., & Burdmann, E. A. (2005) · American Journal of Nephrology · doi:10.1159/000086569 · Cited by 28
Some Phytochemicals and Anti-inflammation Effect of Juice from Tiliacora triandra Leaves
Weerawatanakorn, M., Rojsuntornkitti, K., Pan, M., & Wongwaiwech, D. (2018) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-6-1-6 · Cited by 27
Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly: The Example of Licofelone
Cicero, A. F. G., Derosa, G., & Gaddi, A. V. (2005) · Drugs & Aging · doi:10.2165/00002512-200522050-00004 · Cited by 27
Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review
Mathew, S. T., Gayathri Devi, S., Prasanth, V. V., & Vinod, B. (2011) · ISRN Pharmacology · doi:10.5402/2011/480291 · Cited by 27
Zhang, X., Cui, H. L., Shu-mei, Z., Lu, Y., Yuan, H., Zhang, L., Wang, H., & Du, R. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148516 · Cited by 27
Lee, Y. S., Hur, S., & Kim, T. ‐. (2014) · Allergy · doi:10.1111/all.12356 · Cited by 26
Heo, Y. M., Lee, D., Mun, S., Kim, M., Baek, C., Lee, H., Yun, S. K., Kang, S., & Han, K. (2023) · Genes & Genomics · doi:10.1007/s13258-023-01471-w · Cited by 25
Saravanan, G., Alagarsamy, V., & Prakash, C. R. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0037-7 · Cited by 25
Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor
Xu, G., Liu, F., Ao, G., He, S.-Y., Ju, M., Zhao, Y., & Xue, T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.062 · Cited by 25
Choi, D., Koppula, S., Choi, M., & Suk, K. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.525220 · Cited by 25
Khalil, N. A., Ahmed, E. M., Mohamed, K. O., & Zaitone, S. A. (2013) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c13-00261 · Cited by 25
Shih, T., Liu, M.-H., Li, C.-W., & Kuo, C.-F. (2018) · Molecules · doi:10.3390/molecules23030597 · Cited by 25
Drug–drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity
Nalamachu, S. R., Pergolizzi, J. V., Raffa, R. B., Lakkireddy, D., & Taylor, R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.924924 · Cited by 24
Kondreddy, V. K. R., & Kamatham, A. N. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2016.1147578 · Cited by 23
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies
Shahbazi, S., Sahrawat, T. R., Ray, M., Dash, S., Kar, D., & Singh, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156156 · Cited by 22
Xavier‐Elsas, P., Queto, T., Mendonça‐Sales, S. C., Elsas, M., Kanaoka, Y., & Lam, B. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707586 · Cited by 22
Álvarez, S., Blanco, A., Fresno, M., & Muñoz‐Fernández, M. Á. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06646.x · Cited by 20
Shojo, H., Borlongan, C. V., & Mabuchi, T. (2017) · Cell Transplantation · doi:10.1177/0963689717715169 · Cited by 20
From Bench to Bedside: What Do We Know about Imidazothiazole Derivatives So Far?
Guo, M., Yu, X., Zhu, Y. Z., & Yu, Y. (2023) · Molecules · doi:10.3390/molecules28135052 · Cited by 19
Paracetamol: unconventional uses of a well-known drug
Bloukh, S., Wazaify, M., & Matheson, C. (2021) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riab058 · Cited by 19
Yegireddy, M., Nadoor, P., Rao, S., Pavithra, B. H., Rajashekaraiah, R., Ramachandrappa, S. C., Halemani, G. M., Mannem, S., Prasad, T. N. V. K. V., & Sunilchandra, U. (2022) · Molecules · doi:10.3390/molecules27217312 · Cited by 19
Dilshara, M. G., Lee, K., Lee, C.-M., Choi, Y. H., Lee, H., Choi, I., & Kim, G. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.10.030 · Cited by 19
Lee, S., Choi, Y. H., Kim, Y. S., Min, Y. K., Rhee, M., & Kim, S. H. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.11.014 · Cited by 19
2,3-Diarylxanthones as Potential Inhibitors of Arachidonic Acid Metabolic Pathways
Santos, C. M. M., Ribeiro, D., Silva, A. M. S., & Fernandes, E. G. R. (2017) · Inflammation · doi:10.1007/s10753-017-0540-6 · Cited by 18
Hung, Y.-C., Hsu, C., Chung, C., & Huang, T. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1233-7 · Cited by 18
Metadata
- Authors
- Bertolini, A., Ottani, A., & Sandrini, M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Corresponding author
- Sandrini, M.
- ORCID
- Ottani, A.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-05-01
- Volume
- 9
- Issue
- 10
- Pages
- 1033-1043
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2123833658
- Cited by
- 158
- References
- 0
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 4 · 2018: 11 · 2017: 13 · 2016: 11 · 2015: 11 · 2014: 8 · 2013: 5 · 2012: 12
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- COX-2 inhibitors, nonsteroidal anti-inflammatory drugs, cyclooxygenase-1, cyclooxygenase-2, 5-lipoxygenase inhibition, leukotrienes, prostaglandins, gastrointestinal toxicity, nephrotoxicity, cardioprotection, prostacyclin, TNF-α, rheumatic diseases, adverse drug reactions, nitric oxide, gastroprotective agents
- MeSH terms
- Animals, Anti-Inflammatory Agents, Non-Steroidal, Capillary Permeability, Gastrointestinal Diseases, Humans, Isoenzymes, Lipoxygenase, Membrane Proteins, Pain, Prostaglandin-Endoperoxide Synthases, Rheumatic Diseases, Synovial Membrane, Leukotrienes, Cyclooxygenase Inhibitors, Neurodegenerative Diseases, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.